Author

Nagaraj Velugonda

Observed name: N. Velugonda

Institution: Nizam's Institute of Medical Sciences

Observed institution: Nizam's Institute of Medical Sciences

ORCID: 0000-0003-2855-1229

Observed ORCID: 0000-0003-2855-1229

OpenAlex ID: A5035001638

AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

2023 · Meher Bolisetti Gayatri, Rama Krishna Kancha, et al. · Cell Death Discovery · 14

Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia

2023 · Meher Bolisetti Gayatri, Rama Krishna Kancha, et al. · FEBS Journal · 9

Clinical, Morphological, and Molecular Study of Diffuse WHO Grade II and III Astrocytomas: A Retrospective Analysis from a Single Tertiary Care Institute

2021 · Ramya Lakshmi Veduruvada, Megha S. Uppin, et al. · Indian Journal of Medical and Paediatric Oncology · 1

AMPK Signalling Rewires WWP1 mediated RUNX1 Ubiquitination in CML Progression

2026 · Abhayananda Behera, Sri Charitha Gorantla, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling

2026 · Meher Bolisetti Gayatri, Abhayananda Behera, et al. · Cell Death

A Clinical Assessment of the RT-LAMP-Based Colorimetric Diagnostic Method for COVID-19 with Improved Primers Sets

2023 · S. Sarkar, D. Balasubramanian, et al. · Applied Biochemistry and Microbiology

Works count: 6

Citation count: 24

H-index: 2

I10-index: 1